HLA-C |
Expressed by EVTs |
Some studies suggest that women with preeclampsia are more likely to have inhibitory KIR genotypes whereby interactions between HLA-C and KIR on NK cells fails to stimulate release of pro-migratory chemokines/cytokines and thus result in defective spiral artery remodeling |
Presents pathogen-derived peptides to maternal T and NK cells and activates their cytotoxic responses for infection control |
Interaction between HLA-C and KIRs stimulates NK cells to release chemokines and cytokines promoting trophoblast migration and spiral artery remodeling/physiologic conversion |
HLA-E |
Expressed by EVTs |
Dysregulation/dysfunction in preeclampsia needs to be further investigated |
Presents a limited set of viral pathogen-derived peptides to maternal T and NK cells and activates their cytotoxic responses for infection control |
Protects trophoblasts from NK cell-mediated lysis via interactions with CD94/NKG2A receptors |
HLA-F |
Expressed by EVTs |
Dysregulation/dysfunction in preeclampsia needs to be further investigated |
Genetic variants causing reduced expression associated with decreased fertility, supporting as-yet undefined role in regulating NK cell activity at maternal-fetal interface |
HLA-G |
Expressed by both villous trophoblasts and EVTs |
Decreased placental and circulating HLA-G levels are observed in preeclampsia and are associated with deficient spiral artery remodeling, decreased numbers of Tregs and increased expression of pro-inflammatory cytokines |
Promotes maternal tolerance of the semi-allogenic fetus by inhibiting cytotoxic activity of maternal T and NK cells, and promoting the generation and persistence of Tregs |
Promotes physiologic conversion/spiral artery remodeling by stimulating NK cells to release pro-migratory and proangiogenic chemokines and cytokines. Also interacts with endothelial cells via CD160 |